Ligand Pharmaceuticals (LGND) Equity Ratio: 2010-2025
Historic Equity Ratio for Ligand Pharmaceuticals (LGND) over the last 14 years, with Sep 2025 value amounting to 0.64.
- Ligand Pharmaceuticals' Equity Ratio fell 26.96% to 0.64 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.64, marking a year-over-year decrease of 26.96%. This contributed to the annual value of 0.88 for FY2024, which is 0.96% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Equity Ratio of 0.64 as of Q3 2025, which was down 26.33% from 0.87 recorded in Q2 2025.
- In the past 5 years, Ligand Pharmaceuticals' Equity Ratio ranged from a high of 0.89 in Q2 2024 and a low of 0.58 during Q1 2021.
- In the last 3 years, Ligand Pharmaceuticals' Equity Ratio had a median value of 0.88 in 2025 and averaged 0.85.
- As far as peak fluctuations go, Ligand Pharmaceuticals' Equity Ratio rose by 24.63% in 2022, and later declined by 26.96% in 2025.
- Ligand Pharmaceuticals' Equity Ratio (Quarterly) stood at 0.63 in 2021, then increased by 23.79% to 0.78 in 2022, then increased by 13.65% to 0.89 in 2023, then decreased by 0.96% to 0.88 in 2024, then dropped by 26.96% to 0.64 in 2025.
- Its Equity Ratio was 0.64 in Q3 2025, compared to 0.87 in Q2 2025 and 0.88 in Q1 2025.